Vimarsana
Biggest News Aggregation in the World

Daniel Vt Catenacci News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daniel Vt Catenacci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daniel Vt Catenacci Today - Breaking & Trending Today

This Week In Securities Litigation (Week of August 28, 2023) - Vimarsana News

This Week In Securities Litigation (Week of August 28, 2023)

Summer is heading for its traditional close at Labor Day as many have either returned to school or are finalizing their plans. The Commission…

Ex-UChicago Professor Avoids Prison For Insider Trading - Vimarsana News

Ex-UChicago Professor Avoids Prison For Insider Trading

A former University of Chicago professor who pled guilty to insider trading with information about a positive cancer drug trial he was involved in won't serve prison time after an Illinois federal judge sentenced him Wednesday to time served and a year of supervised release.

Source: law360.com
Investigation Newsletter: Eli Lilly Accused of Defrauding Government in $60 Million Qui Tam Suit | ArentFox Schiff - Vimarsana News

Investigation Newsletter: Eli Lilly Accused of Defrauding Government in $60 Million Qui Tam Suit | ArentFox Schiff

Eli Lilly Accused of Defrauding Government in $60 Million Qui Tam Suit - In a qui tam suit alleging that Eli Lilly and Co. (“Eli Lilly”) violated the False Claims Act, a...

U. Of Chicago Prof Pleads Not Guilty To Insider Trading - Vimarsana News

U. Of Chicago Prof Pleads Not Guilty To Insider Trading

A physician and professor at the University of Chicago entered a plea of not guilty Tuesday to charges that he traded on inside information from Five Prime Therapeutics Inc. ahead of the publication of positive results of a drug trial for its leading cancer drug bemarituzumab.

Source: law360.com
Chicago Oncologist Charged With Insider Trading - Vimarsana News

Chicago Oncologist Charged With Insider Trading

Dr Daniel Catenacci, the lead investigator in a clinical trial for the drug bemarituzumab, has been charged with violating the antifraud provisions of the federal securities laws.